Guerard W Byrne from Princess Anne, MD, age 67

view source

Work:

Associate Professor

view source

Inhibition Of Xenoreactive Antibodies
view source
US Patent:

6572867, Jun 3, 2003
Filed:

Apr 15, 1999
Appl. No.:

09/292153
Inventors:

Alexander Schwarz - Plainsboro NJ
Guerard W. Byrne - Allentown NJ
Thomas A. Davis - Newtown PA
Lisa E. Diamond - Princeton NJ
John S. Logan - Robbinsville NJ
Assignee:

Baxter International Inc. - Deerfield IL
International Classification:

A61K 4726
US Classification:

4242781, 4241841, 4241931, 4241941, 4242791, 4242801, 514 23
Abstract:

One aspect of the present invention relates to methods and compositions for attenuating xenograft rejection by administering, to an animal receiving the xenograft, an amount of a polymer-derivatized xenoantigen (hereinafter âxenopolymerâ) effective for inhibiting or lessening the severity of hyperacute rejection response (HAR), or other immunological response to the graft, that is dependent on the presence of the xenoantigen on the grafted tissues or cells. In certain embodiments, the xenopolymer is administered in an amount sufficient to neutralize host antibodies (âxenoreactive antibodiesâ or âXNAâ) immunoreactive with the xenoantigen. The xenopolymer may additionally, or alternatively, be used as a tolerogen (or anergen) for the xenoantigen, e. g. , able to suppress, to some degree, the production/secretion of XNAs by the immune system of the host.

Inhibition Of Xenoreactive Antibodies
view source
US Patent:

20040141944, Jul 22, 2004
Filed:

Mar 28, 2003
Appl. No.:

10/402845
Inventors:

Alexander Schwarz - Plainsboro NJ, US
Guerard Byrne - Allentown NJ, US
Thomas Davis - Newtown PA, US
Lisa Diamond - Princeton NJ, US
John Logan - Robbinsville NJ, US
International Classification:

A61K039/00
C08G063/48
C08G063/91
US Classification:

424/078270, 424/078290, 525/054100
Abstract:

One aspect of the present invention relates to methods and compositions for attenuating xenograft rejection by administering, to an animal receiving the xenograft, an amount of a polymer-derivatized xenoantigen (hereinafter “xenopolymer”) effective for inhibiting or lessening the severity of hyperacute rejection response (HAR), or other immunological response to the graft, that is dependent on the presence of the xenoantigen on the grafted tissues or cells. In certain embodiments, the xenopolymer is administered in an amount sufficient to neutralize host antibodies (“xenoreactive antibodies” or “XNA”) immunoreactive with the xenoantigen. The xenopolymer may additionally, or alternatively, be used as a tolerogen (or anergen) for the xenoantigen, e.g., able to suppress, to some degree, the production/secretion of XNAs by the immune system of the host.

Inhibition Of Xenoreactive Antibodies
view source
US Patent:

20080124396, May 29, 2008
Filed:

Oct 31, 2007
Appl. No.:

11/932737
Inventors:

Alexander Schwarz - Plainsboro NJ, US
Guerard W. Byrne - Allentown NJ, US
Thomas A. Davis - Newtown PA, US
Lisa E. Diamond - Princeton NJ, US
John S. Logan - Robbinsville NJ, US
Assignee:

Mayo Foundation for Medical Education and Research - Rochester MN
International Classification:

A61K 47/32
A61P 37/06
A61K 9/00
A61K 38/19
A61K 39/395
US Classification:

424486, 424 851, 4241301
Abstract:

One aspect of the present invention relates to methods and compositions for attenuating xenograft rejection by administering, to an animal receiving the xenograft, an amount of a polymer-derivatized xenoantigen (hereinafter “xenopolymer”) effective for inhibiting or lessening the severity of hyperacute rejection response (HAR), or other immunological response to the graft, that is dependent on the presence of the xenoantigen on the grafted tissues or cells. In certain embodiments, the xenopolymer is administered in an amount sufficient to neutralize host antibodies (“xenoreactive antibodies” or “XNA”) immunoreactive with the xenoantigen. The xenopolymer may additionally, or alternatively, be used as a tolerogen (or anergen) for the xenoantigen, e.g., able to suppress, to some degree, the production/secretion of XNAs by the immune system of the host.

Genetically Modified Heart Valve Xenografts
view source
US Patent:

20090043383, Feb 12, 2009
Filed:

Mar 28, 2005
Appl. No.:

10/594944
Inventors:

Christopher G.A. McGregor - Rochester MN, US
Guerard W. Byrne - Rochester MN, US
William R. Davies - Cambridgeshire, GB
John S. Logan - Robbinsville NJ, US
Assignee:

MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH - Rochester MN
International Classification:

A61F 2/24
US Classification:

623 242, 600 36
Abstract:

The invention relates to heart valve xenografts from transgenic pigs having a disruption of an α1-3 galactosyl transferase nucleic acid sequence and use of the xenografts for treating a patient.

Methods And Materials For Reducing Cardiac Xenograft Rejection
view source
US Patent:

20130111614, May 2, 2013
Filed:

Apr 11, 2011
Appl. No.:

13/696478
Inventors:

Christopher G.A. McGregor - Rochester MN, US
Guerard W. Byrne - Rochester MN, US
Assignee:

MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH - Rochester MN
International Classification:

A61K 39/00
A61K 35/34
US Classification:

800 17, 4241851, 424 937, 435 721
Abstract:

This document provides methods and materials involved in reducing cardiac xenograft rejection. For example, methods and materials for preparing transgenic pigs expressing reduced or no endogenous Sdor SDa-like glycans derived from the porcine β1,4 N-acetyl-galactosaminyl transferase 2 (B4GALNT2) glycosyltransferase and/or reduced or no endogenous α-Gal antigens, methods and materials for modifying the xenograft recipient's immunological response to non-Gal antigens (e.g. CD46, CD59, CD9, PROCR, and ANXA2) to reduce cardiac xenograft rejection, and methods and materials for monitoring the progress of xenotransplant immunologic rejection are provided.

Tetracycline Repressor-Mediated Binary Regulation System For Control Of Gene Expression In Transgenic Mice
view source
US Patent:

59171227, Jun 29, 1999
Filed:

Feb 24, 1995
Appl. No.:

8/392771
Inventors:

Guerard Byrne - East Windsor NJ
International Classification:

C12N 500
C12N 1500
C12N 1509
C12N 1563
US Classification:

800 18
Abstract:

The present invention relates to a tetracycline repressor-mediated binary regulation system for the control of gene expression in transgenic mice. It is based, at least in part, on the discovery that, in a transgenic mouse that carries a first transgene under the control of a modified promoter comprising a tetR operator sequence and a second transgene encoding the tetR protein, expression of the first transgene may be efficiently induced by administering tetracycline to the mouse.

Methods And Materials For Reducing Cardiac Xenograft Rejection
view source
US Patent:

20170360906, Dec 21, 2017
Filed:

Apr 24, 2017
Appl. No.:

15/494976
Inventors:

- Rochester MN, US
Guerard W. Byrne - Rochester MN, US
Assignee:

Mayo Foundation for Medical Education and Research - Rochester MN
International Classification:

A61K 39/00
C12N 15/85
A01K 67/027
A61K 35/34
A61K 38/00
Abstract:

This document provides methods and materials involved in reducing cardiac xenograft rejection. For example, methods and materials for preparing transgenic pigs expressing reduced or no endogenous Sdor SDa-like glycans derived from the porcine β1,4 N-acetyl-galactosaminyl transferase 2 (B4GALNT2) glycosyltransferase and/or reduced or no endogenous α-Gal antigens, methods and materials for modifying the xenograft recipient's immunological response to non-Gal antigens (e.g. CD46, CD59, CD9, PROCR, and ANXA2) to reduce cardiac xenograft rejection, and methods and materials for monitoring the progress of xenotransplant immunologic rejection are provided.